Mortality risk assessment in type 2 cardiorenal syndrome: comparative study
Abstract Background Type 2 cardiorenal syndrome is a serious, life threatening clinical condition, associated with adverse clinical outcomes. Although several prognostic biomarkers have been reported, early and accurate prognosis still remains a challenge. Aims This study was aimed to identify the b...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2020-11, Vol.41 (Supplement_2) |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_2 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 41 |
| creator | Bivol, E Grib, L Grajdieru, R Grejdieru, A Mazur-Nicorici, L Vetrila, S Samohvalov, E Tcaciuc, A Filimon, S Sumarga, N |
| description | Abstract
Background
Type 2 cardiorenal syndrome is a serious, life threatening clinical condition, associated with adverse clinical outcomes. Although several prognostic biomarkers have been reported, early and accurate prognosis still remains a challenge.
Aims
This study was aimed to identify the best prognostic renal markers, to develop and validate an individualized predictive formula for the mortality risk in type 2 cardiorenal patients.
Methods
A total of 170 hospitalized patients (between 2014 and 2018) were included in this study. Renal function and glomerular filtration rate (GFR) was assessed using the most popular formulas for GFR estimation: the Cockcroft-Gault (CG), the four-variable Simplified Modification of Diet in Renal Disease (sMDRD), CKD-Epidemiology Collaboration (CKD-EPI) based on serum cystatin-C, creatinine and their combination, and the simple cystatin-C formula. All data were used to screen the predictors via univariate and multivariate analyses. A model was developed based on these predictors and validated by internal validation. The model validation comprised discriminative ability determined by the area under the curve (AUC) of receiver operating characteristic (ROC) curve and the predictive accuracy by calibration plots.
Results
During a mean follow-up of 6 months, 29 (16.2%) deaths were recorded. In an adjusted model, renal biomarkers and estimated glomerular filtration rate showed different prognostic value according to the area under the curve. Area under the ROC curve was 0.58 (95% CI:0.47–0.69, P=0.05) for serum creatinine, 0.67 (95% CI: 0.56–0.79, P |
| doi_str_mv | 10.1093/ehjci/ehaa946.1160 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_1160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.1160</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.1160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c810-5c98f44a231092e388b2a278a70e068904956ac1a44b8e11dcbed88db53eafa73</originalsourceid><addsrcrecordid>eNqNkEtOwzAYhC0EEqFwAVa-QIrt2I7NDlW8RBGbLthFf-w_wiUv2SlSbk9LewA2M5uZ0egj5JazJWe2uMOvrQt7BbBSLznX7IxkXAmRWy3VOckYtyrX2nxekquUtowxo7nOyNv7ECdowzTTGNI3hZQwpQ77iYaeTvOIVFAH0YchYg8tTXPv49DhPXVDN0KEKfwgTdPOz9fkooE24c3JF2Tz9LhZveTrj-fX1cM6d4azXDlrGilBFPvnAgtjagGiNFAyZNpYJq3S4DhIWRvk3LsavTG-VgVCA2WxIOI46-KQUsSmGmPoIM4VZ9WBRvVHozrRqA409qX8WBp243_yv7pGZXs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mortality risk assessment in type 2 cardiorenal syndrome: comparative study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Bivol, E ; Grib, L ; Grajdieru, R ; Grejdieru, A ; Mazur-Nicorici, L ; Vetrila, S ; Samohvalov, E ; Tcaciuc, A ; Filimon, S ; Sumarga, N</creator><creatorcontrib>Bivol, E ; Grib, L ; Grajdieru, R ; Grejdieru, A ; Mazur-Nicorici, L ; Vetrila, S ; Samohvalov, E ; Tcaciuc, A ; Filimon, S ; Sumarga, N</creatorcontrib><description><![CDATA[Abstract
Background
Type 2 cardiorenal syndrome is a serious, life threatening clinical condition, associated with adverse clinical outcomes. Although several prognostic biomarkers have been reported, early and accurate prognosis still remains a challenge.
Aims
This study was aimed to identify the best prognostic renal markers, to develop and validate an individualized predictive formula for the mortality risk in type 2 cardiorenal patients.
Methods
A total of 170 hospitalized patients (between 2014 and 2018) were included in this study. Renal function and glomerular filtration rate (GFR) was assessed using the most popular formulas for GFR estimation: the Cockcroft-Gault (CG), the four-variable Simplified Modification of Diet in Renal Disease (sMDRD), CKD-Epidemiology Collaboration (CKD-EPI) based on serum cystatin-C, creatinine and their combination, and the simple cystatin-C formula. All data were used to screen the predictors via univariate and multivariate analyses. A model was developed based on these predictors and validated by internal validation. The model validation comprised discriminative ability determined by the area under the curve (AUC) of receiver operating characteristic (ROC) curve and the predictive accuracy by calibration plots.
Results
During a mean follow-up of 6 months, 29 (16.2%) deaths were recorded. In an adjusted model, renal biomarkers and estimated glomerular filtration rate showed different prognostic value according to the area under the curve. Area under the ROC curve was 0.58 (95% CI:0.47–0.69, P=0.05) for serum creatinine, 0.67 (95% CI: 0.56–0.79, P<0.05) for serum cystatin-C; 0.76±0.05 (95% CI: 0.67–0.82, P<0.01) for CKD-EPI formula based on serum cystatin-C; 0.73±0.06 (95% CI: 0.65–0.79, P<0.01) for simple formula based on serum cystatin-C; 0.72±0.05 (95% CI: 0.64–0.79, P<0.01) for CKD-EPI formula based on serum cystatin-C and serum creatinine; 0.617±0.06 (95% CI: 0.53–0.69, P<0.01) for CKD-EPI formula based on serum creatinine; 0.615±0.06 (95% CI: 0.53–0.69, P<0.01) for sMDRD formula and 0.58±0.07 (95% CI: 0.53–0.69, P<0.01) for CG formula. Multivariate logistic regression revealed that cardiovascular disease length, psycho-emotional stress, NYHA class, hemoglobin, serum cystatin-C and GFR using the simple cystatin-C formula were independently associated with mortality in type 2 cardorenal syndrome. A model developed based on the seven variables had a specificity of 79.31%, and sensitivity 78.72% (P<0.01), while AUC was 0.792 (P<0.01), in internal validation.
Conclusion
GFR is an independent predictor for short term mortality of type 2 cardiorenal syndrome. Cystatin-C based formulas seems to offer improved prognostication in this population, while CG formula and serum creatinine fail to predict short term mortality The proposed model could predict the individualized mortality risk with good accuracy, high discrimination, and potential clinical applicability in cardiorenal patients.
Funding Acknowledgement
Type of funding source: None]]></description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.1160</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bivol, E</creatorcontrib><creatorcontrib>Grib, L</creatorcontrib><creatorcontrib>Grajdieru, R</creatorcontrib><creatorcontrib>Grejdieru, A</creatorcontrib><creatorcontrib>Mazur-Nicorici, L</creatorcontrib><creatorcontrib>Vetrila, S</creatorcontrib><creatorcontrib>Samohvalov, E</creatorcontrib><creatorcontrib>Tcaciuc, A</creatorcontrib><creatorcontrib>Filimon, S</creatorcontrib><creatorcontrib>Sumarga, N</creatorcontrib><title>Mortality risk assessment in type 2 cardiorenal syndrome: comparative study</title><title>European heart journal</title><description><![CDATA[Abstract
Background
Type 2 cardiorenal syndrome is a serious, life threatening clinical condition, associated with adverse clinical outcomes. Although several prognostic biomarkers have been reported, early and accurate prognosis still remains a challenge.
Aims
This study was aimed to identify the best prognostic renal markers, to develop and validate an individualized predictive formula for the mortality risk in type 2 cardiorenal patients.
Methods
A total of 170 hospitalized patients (between 2014 and 2018) were included in this study. Renal function and glomerular filtration rate (GFR) was assessed using the most popular formulas for GFR estimation: the Cockcroft-Gault (CG), the four-variable Simplified Modification of Diet in Renal Disease (sMDRD), CKD-Epidemiology Collaboration (CKD-EPI) based on serum cystatin-C, creatinine and their combination, and the simple cystatin-C formula. All data were used to screen the predictors via univariate and multivariate analyses. A model was developed based on these predictors and validated by internal validation. The model validation comprised discriminative ability determined by the area under the curve (AUC) of receiver operating characteristic (ROC) curve and the predictive accuracy by calibration plots.
Results
During a mean follow-up of 6 months, 29 (16.2%) deaths were recorded. In an adjusted model, renal biomarkers and estimated glomerular filtration rate showed different prognostic value according to the area under the curve. Area under the ROC curve was 0.58 (95% CI:0.47–0.69, P=0.05) for serum creatinine, 0.67 (95% CI: 0.56–0.79, P<0.05) for serum cystatin-C; 0.76±0.05 (95% CI: 0.67–0.82, P<0.01) for CKD-EPI formula based on serum cystatin-C; 0.73±0.06 (95% CI: 0.65–0.79, P<0.01) for simple formula based on serum cystatin-C; 0.72±0.05 (95% CI: 0.64–0.79, P<0.01) for CKD-EPI formula based on serum cystatin-C and serum creatinine; 0.617±0.06 (95% CI: 0.53–0.69, P<0.01) for CKD-EPI formula based on serum creatinine; 0.615±0.06 (95% CI: 0.53–0.69, P<0.01) for sMDRD formula and 0.58±0.07 (95% CI: 0.53–0.69, P<0.01) for CG formula. Multivariate logistic regression revealed that cardiovascular disease length, psycho-emotional stress, NYHA class, hemoglobin, serum cystatin-C and GFR using the simple cystatin-C formula were independently associated with mortality in type 2 cardorenal syndrome. A model developed based on the seven variables had a specificity of 79.31%, and sensitivity 78.72% (P<0.01), while AUC was 0.792 (P<0.01), in internal validation.
Conclusion
GFR is an independent predictor for short term mortality of type 2 cardiorenal syndrome. Cystatin-C based formulas seems to offer improved prognostication in this population, while CG formula and serum creatinine fail to predict short term mortality The proposed model could predict the individualized mortality risk with good accuracy, high discrimination, and potential clinical applicability in cardiorenal patients.
Funding Acknowledgement
Type of funding source: None]]></description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkEtOwzAYhC0EEqFwAVa-QIrt2I7NDlW8RBGbLthFf-w_wiUv2SlSbk9LewA2M5uZ0egj5JazJWe2uMOvrQt7BbBSLznX7IxkXAmRWy3VOckYtyrX2nxekquUtowxo7nOyNv7ECdowzTTGNI3hZQwpQ77iYaeTvOIVFAH0YchYg8tTXPv49DhPXVDN0KEKfwgTdPOz9fkooE24c3JF2Tz9LhZveTrj-fX1cM6d4azXDlrGilBFPvnAgtjagGiNFAyZNpYJq3S4DhIWRvk3LsavTG-VgVCA2WxIOI46-KQUsSmGmPoIM4VZ9WBRvVHozrRqA409qX8WBp243_yv7pGZXs</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Bivol, E</creator><creator>Grib, L</creator><creator>Grajdieru, R</creator><creator>Grejdieru, A</creator><creator>Mazur-Nicorici, L</creator><creator>Vetrila, S</creator><creator>Samohvalov, E</creator><creator>Tcaciuc, A</creator><creator>Filimon, S</creator><creator>Sumarga, N</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Mortality risk assessment in type 2 cardiorenal syndrome: comparative study</title><author>Bivol, E ; Grib, L ; Grajdieru, R ; Grejdieru, A ; Mazur-Nicorici, L ; Vetrila, S ; Samohvalov, E ; Tcaciuc, A ; Filimon, S ; Sumarga, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c810-5c98f44a231092e388b2a278a70e068904956ac1a44b8e11dcbed88db53eafa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bivol, E</creatorcontrib><creatorcontrib>Grib, L</creatorcontrib><creatorcontrib>Grajdieru, R</creatorcontrib><creatorcontrib>Grejdieru, A</creatorcontrib><creatorcontrib>Mazur-Nicorici, L</creatorcontrib><creatorcontrib>Vetrila, S</creatorcontrib><creatorcontrib>Samohvalov, E</creatorcontrib><creatorcontrib>Tcaciuc, A</creatorcontrib><creatorcontrib>Filimon, S</creatorcontrib><creatorcontrib>Sumarga, N</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bivol, E</au><au>Grib, L</au><au>Grajdieru, R</au><au>Grejdieru, A</au><au>Mazur-Nicorici, L</au><au>Vetrila, S</au><au>Samohvalov, E</au><au>Tcaciuc, A</au><au>Filimon, S</au><au>Sumarga, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality risk assessment in type 2 cardiorenal syndrome: comparative study</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract><![CDATA[Abstract
Background
Type 2 cardiorenal syndrome is a serious, life threatening clinical condition, associated with adverse clinical outcomes. Although several prognostic biomarkers have been reported, early and accurate prognosis still remains a challenge.
Aims
This study was aimed to identify the best prognostic renal markers, to develop and validate an individualized predictive formula for the mortality risk in type 2 cardiorenal patients.
Methods
A total of 170 hospitalized patients (between 2014 and 2018) were included in this study. Renal function and glomerular filtration rate (GFR) was assessed using the most popular formulas for GFR estimation: the Cockcroft-Gault (CG), the four-variable Simplified Modification of Diet in Renal Disease (sMDRD), CKD-Epidemiology Collaboration (CKD-EPI) based on serum cystatin-C, creatinine and their combination, and the simple cystatin-C formula. All data were used to screen the predictors via univariate and multivariate analyses. A model was developed based on these predictors and validated by internal validation. The model validation comprised discriminative ability determined by the area under the curve (AUC) of receiver operating characteristic (ROC) curve and the predictive accuracy by calibration plots.
Results
During a mean follow-up of 6 months, 29 (16.2%) deaths were recorded. In an adjusted model, renal biomarkers and estimated glomerular filtration rate showed different prognostic value according to the area under the curve. Area under the ROC curve was 0.58 (95% CI:0.47–0.69, P=0.05) for serum creatinine, 0.67 (95% CI: 0.56–0.79, P<0.05) for serum cystatin-C; 0.76±0.05 (95% CI: 0.67–0.82, P<0.01) for CKD-EPI formula based on serum cystatin-C; 0.73±0.06 (95% CI: 0.65–0.79, P<0.01) for simple formula based on serum cystatin-C; 0.72±0.05 (95% CI: 0.64–0.79, P<0.01) for CKD-EPI formula based on serum cystatin-C and serum creatinine; 0.617±0.06 (95% CI: 0.53–0.69, P<0.01) for CKD-EPI formula based on serum creatinine; 0.615±0.06 (95% CI: 0.53–0.69, P<0.01) for sMDRD formula and 0.58±0.07 (95% CI: 0.53–0.69, P<0.01) for CG formula. Multivariate logistic regression revealed that cardiovascular disease length, psycho-emotional stress, NYHA class, hemoglobin, serum cystatin-C and GFR using the simple cystatin-C formula were independently associated with mortality in type 2 cardorenal syndrome. A model developed based on the seven variables had a specificity of 79.31%, and sensitivity 78.72% (P<0.01), while AUC was 0.792 (P<0.01), in internal validation.
Conclusion
GFR is an independent predictor for short term mortality of type 2 cardiorenal syndrome. Cystatin-C based formulas seems to offer improved prognostication in this population, while CG formula and serum creatinine fail to predict short term mortality The proposed model could predict the individualized mortality risk with good accuracy, high discrimination, and potential clinical applicability in cardiorenal patients.
Funding Acknowledgement
Type of funding source: None]]></abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.1160</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2020-11, Vol.41 (Supplement_2) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ehjci_ehaa946_1160 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Mortality risk assessment in type 2 cardiorenal syndrome: comparative study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A01%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20risk%20assessment%20in%20type%202%20cardiorenal%20syndrome:%20comparative%20study&rft.jtitle=European%20heart%20journal&rft.au=Bivol,%20E&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.1160&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.1160%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.1160&rfr_iscdi=true |